Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials

Cardiovascular Revascularization Medicine

Volumn 14, Issue 6, 2013, Pages 349-355

  Hakeem, Abdul ^a   Marmagkiolis, Konstantinos ^b   Hacioglu, Yalcin ^a   Uretsky, Barry F ^a   Gundogdu, Betul ^a   Leesar, Massoud ^c   Bailey, Steven R ^d   Cilingiroglu, Mehmet ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Citizens Memorial Hospital Heart and Vascular Institute   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e ARKANSAS HEART HOSPITAL   (United States)

Author keywords

Meta analysis; Patent foramen ovale; Structural interventions

Indexed keywords

CEREBROVASCULAR ACCIDENT; DEATH; EMBOLISM; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PATENT FORAMEN OVALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSIENT ISCHEMIC ATTACK; VASCULAR IMPLANT; VASCULAR OCCLUDER;

META-ANALYSIS; PATENT FORAMEN OVALE; STRUCTURAL INTERVENTIONS;

ADULT; AGED; CARDIAC CATHETERIZATION; EMBOLISM; FEMALE; FORAMEN OVALE, PATENT; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; SEPTAL OCCLUDER DEVICE; TREATMENT OUTCOME;

EID: 84888202807     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2013.08.010     Document Type: Review

References (28)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Executive summary: heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
2. Lechat P., Mas J.L., Lascault G., Loron P., Theard M., Klimczac M., et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148-1152.
3. Hagen P.T., Scholz D.G., Edwards W.D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984, 59:17-20.
4. Heinisch C., Bertog S., Wunderlich N., Majunke N., Baranowski A., Leetz M., et al. Percutaneous closure of the patent foramen ovale using the HELEX(R) Septal Occluder: acute and long-term results in 405 patients. EuroIntervention 2012, 8:717-723.
5. Windecker S., Wahl A., Chatterjee T., Garachemani A., Eberli F.R., Seiler C., et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000, 101:893-898.
6. Anzola G.P., Morandi E., Casilli F., Onorato E. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. Stroke 2004, 35:2140-2144.
7. Martin F., Sanchez P.L., Doherty E., Colon-Hernandez P.J., Delgado G., Inglessis I., et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002, 106:1121-1126.
8. Agarwal S., Bajaj N.S., Kumbhani D.J., Tuzcu E.M., Kapadia S.R. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv 2012, 7:777-789. 10.1016/j.jcin.2012.02.021.
9. Wahl A., Jüni P., Mono M.L., Kalesan B., Praz F., Geister L., et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation 2012, 125(6):803-812.
10. Furlan A.J., Reisman M., Massaro J., Mauri L., Adams H., Albers G.W., et al. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke 2010, 41:2872-2883.
11. O'Gara P.T., Messe S.R., Tuzcu E.M., Catha G., Ring J.C. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2009, 53:2014-2018.
12. Meier B., Kalesan B., Mattle H.P., Khattab A.A., Hildick-Smith D., Dudek D., et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013, 368:1083-1091.
13. Carroll J.D., Saver J.L., Thaler D.E., Smalling R.W., Berry S., MacDonald L.A., et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013, 368:1092-1100.
14. Booth A., Clarke M., Ghersi D., Moher D., Petticrew M., Stewart L. An international registry of systematic-review protocols. Lancet 2011, 377:108-109.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
16. Higgins J.P.T., Green S. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England 2008, Hoboken, NJ, Wiley-Blackwell.
17. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
18. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
19. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Abaci A., Unlu S., Alsancak Y., Kaya U., Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: Meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv 2013, [Epub ahead of print]. 10.1002/ccd.24875.
21. Li Y., Zhou K., Hua Y., Wang C., Xie L., Fang J., et al. Amplatzer occluder versus CardioSEAL/STARFlex occluder: a meta-analysis of the efficacy and safety of transcatheter occlusion for patent foramen ovale and atrial septal defect. Cardiol Young 2012, 1-15.
22. Hornung M., Bertog S.C., Franke J., Id D., Taaffe M., Wunderlich N., et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J 2013, [Epub ahead of print].
23. Li Y., Zhou K., Hua Y., Wang C., Xie L., Fang J., et al. Amplatzer occluder versus CardioSEAL/STARFlex occluder: a meta-analysis of the efficacy and safety of transcatheter occlusion for patent foramen ovale and atrial septal defect. Cardiol Young 2013, 23(4):582-596. [Epub 2012 Dec 3]. 10.1017/S1047951112001424.
24. Staubach S., Steinberg D.H., Zimmermann W., Wawra N., Wilson N., Wunderlich N., et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv 2009, 74:889-895.
25. Agmon Y., Khandheria B.K., Meissner I., Gentile F., Whisnant J.P., Sicks J.D., et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 1999, 99:1942-1944.
26. Kroenke K., Rosmalen J.G. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 2006, 90:603-626.
27. Lipton R.B., Bigal M.E., Diamond M., Freitag F., Reed M.L., Stewart W.F. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
28. Jones T.K., Latson L.A., Zahn E., Fleishman C.E., Jacobson J., Vincent R., et al. Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects. J Am Coll Cardiol 2007, 49:2215-2221.